Algernon Pharmaceuticals Stock EBITDA

AGNPF Stock  USD 0.05  0  5.11%   
Algernon Pharmaceuticals fundamentals help investors to digest information that contributes to Algernon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Algernon OTC Stock. The fundamental analysis module provides a way to measure Algernon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Algernon Pharmaceuticals otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Algernon Pharmaceuticals OTC Stock EBITDA Analysis

Algernon Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Algernon Pharmaceuticals EBITDA

    
  (6.02 M)  
Most of Algernon Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Algernon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Algernon Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (6.02 Million). This is 100.69% lower than that of the Healthcare sector and 106.01% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.15% higher than that of the company.

Algernon EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Algernon Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Algernon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Algernon Pharmaceuticals by comparing valuation metrics of similar companies.
Algernon Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Algernon Fundamentals

About Algernon Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Algernon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Algernon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Algernon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Algernon OTC Stock

Algernon Pharmaceuticals financial ratios help investors to determine whether Algernon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Algernon with respect to the benefits of owning Algernon Pharmaceuticals security.